N/A
Completed N=123
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Source: ClinicalTrials.gov NCT00443534 ↗Enrolled (actual)
123
Serious AEs
28.7%
Results posted
May 2013
Primary outcomePrimary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 119; 35 participants
Summary
This protocol allows subjects who have participated in a previous SU011248 protocol the ability to continue to receive SU011248 after their study has ended.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) |
119; 35 | — |
Eligibility Criteria
Inclusion Criteria
- Participation in a previous SU011248 protocol and are judged by the investigator to have the potential to derive clinical benefit by remaining on SU011248 after the prior protocol ends.
Exclusion Criteria
- Severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
Data sourced from ClinicalTrials.gov (NCT00443534). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.